Latest news with #AESI
&w=3840&q=100)
Business Standard
a day ago
- Health
- Business Standard
Siddaramaiah flags possible Covid vaccine link in heart attack deaths
The Karnataka government on Tuesday announced formation of a committee to study potential side effects of Covid-19 vaccines, including links to heart attacks, amid reports that at least 20 people have died due to cardiac arrest in the state's Hassan district alone over the last one month. 'Owing to this, a committee has been formed under the leadership of Dr Ravindranath, director of Jayadeva Institute of Cardiovascular Science and Research, and they have been instructed to submit a study report within 10 days,' Karnataka Chief Minister Siddaramaiah said in a post on social media platform X. This comes after the Karnataka government had ordered the formation of an expert committee in February to investigate the rising number of sudden deaths among young people, amid growing concerns that these incidents may be linked to Covid vaccine. 'In this regard, the process of examining and analysing heart patients is also underway,' Siddaramaiah added. He alleged in his post that the rushed approval and distribution of the Covid-19 vaccine may also be a contributing factor to these deaths, citing several international studies that have recently suggested a possible link between the vaccines and a rise in heart attacks. 'We, too, value the lives of children, youth, and innocent people who have their entire lives ahead of them, and we share the concerns of their families,' he added. The CM's charge comes even as several studies and experts have highlighted cases of vaccinated people facing adverse events. In May last year, a team of researchers from the Banaras Hindu University (BHU) had claimed that nearly one third of the individuals who received Covaxin (manufactured by Bharat Biotech) were reported to have faced adverse events of special interest (AESI) such as viral upper respiratory tract infections, menstrual abnormalities and Guillain-Barre Syndrome. The Indian Council of Medical Research (ICMR) had later criticised the study, calling it poorly designed, with a poor methodology and critical flaws in the design of the study. The AstraZeneca vaccine, which was manufactured by the Serum Institute of India, was sold in the country under the name Covishield. Siddaramaiah added that the government will investigate the true cause behind the recent spate of sudden deaths in Hassan district and across the state, and take necessary steps to prevent further incidents. 'With this goal, we have already implemented schemes like Hridaya Jyothi and Gruha Arogya to monitor public health. Based on the report from the expert committee under Dr Ravindranath's guidance, necessary actions will also be taken,' he said.
Business Insider
6 days ago
- Business
- Business Insider
Atlas Energy Solutions (AESI) Receives a Buy from RBC Capital
RBC Capital analyst Keith Mackey maintained a Buy rating on Atlas Energy Solutions (AESI – Research Report) yesterday and set a price target of $17.00. The company's shares closed yesterday at $13.86. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Mackey covers the Energy sector, focusing on stocks such as Baker Hughes Company, Patterson-UTI, and Atlas Energy Solutions. According to TipRanks, Mackey has an average return of 16.9% and a 56.70% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Atlas Energy Solutions with a $16.00 average price target. The company has a one-year high of $26.86 and a one-year low of $11.76. Currently, Atlas Energy Solutions has an average volume of 1.86M. Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AESI in relation to earlier this year. Last month, Douglas G Rogers, a Director at AESI bought 7,000.00 shares for a total of $92,820.00.
Yahoo
10-06-2025
- Business
- Yahoo
Atlas Announces Timing of Second Quarter 2025 Earnings Release and Conference Call
AUSTIN, Texas, June 10, 2025--(BUSINESS WIRE)--Atlas Energy Solutions Inc. (NYSE: AESI) ("Atlas" or the "Company") today announced that it will issue its second quarter 2025 earnings release after market close on Monday, August 4, 2025, and will host a conference call to discuss financial and operational results at 9:00am Central Time (10:00am Eastern Time) on Tuesday, August 5, 2025. A live webcast will be available at Please join the webcast at least 10 minutes ahead of the start time to ensure a proper connection and registration. An archived version of the second quarter 2025 earnings materials will be made available on the Company's website. About Atlas Energy Solutions Atlas Energy Solutions Inc. (NYSE: AESI) is a leading solutions provider to the energy industry. Atlas' portfolio of offerings includes oilfield logistics, distributed power systems, and the largest proppant supply network in the Permian Basin. With a focus on leveraging technology, automation, and remote operations to enhance efficiencies, Atlas is centered around a core mission of improving human beings' access to hydrocarbons that power our lives and, by doing so, maximizing value creation for our shareholders. View source version on Contacts Investor Contact Kyle Turlington5918 W Courtyard Drive, Suite #500Austin, Texas 78730United StatesT: 512-220-1200IR@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
10-06-2025
- Business
- Business Wire
Atlas Announces Timing of Second Quarter 2025 Earnings Release and Conference Call
AUSTIN, Texas--(BUSINESS WIRE)--Atlas Energy Solutions Inc. (NYSE: AESI) ('Atlas' or the 'Company') today announced that it will issue its second quarter 2025 earnings release after market close on Monday, August 4, 2025, and will host a conference call to discuss financial and operational results at 9:00am Central Time (10:00am Eastern Time) on Tuesday, August 5, 2025. A live webcast will be available at Please join the webcast at least 10 minutes ahead of the start time to ensure a proper connection and registration. An archived version of the second quarter 2025 earnings materials will be made available on the Company's website. About Atlas Energy Solutions Atlas Energy Solutions Inc. (NYSE: AESI) is a leading solutions provider to the energy industry. Atlas' portfolio of offerings includes oilfield logistics, distributed power systems, and the largest proppant supply network in the Permian Basin. With a focus on leveraging technology, automation, and remote operations to enhance efficiencies, Atlas is centered around a core mission of improving human beings' access to hydrocarbons that power our lives and, by doing so, maximizing value creation for our shareholders.
Yahoo
02-06-2025
- Health
- Yahoo
‘Stealthy' Endocrine Effects of the COVID Vaccine Discussed in the Journal of American Physicians and Surgeons
TUCSON, Ariz., June 02, 2025 (GLOBE NEWSWIRE) -- Endocrine effects that may result from vaccination are deceptively subtle at their onset. Hence, robust and sensitive pharmacovigilance is needed to discover them, writes Jane Orient, M.D., in the summer issue of the Journal of American Physicians and Surgeons. As of Mar 20, 2023, more than 13 billion COVID-19 vaccine doses had been administered worldwide. Vaccine proponents argue that with such huge numbers of vaccinations, a clear signal for endocrinological complications should be detected by current vaccine surveillance. This has not occurred, but not necessarily due to the absence of adverse endocrine events, Dr. Orient writes. There are two approaches to surveillance, she explains: the adverse events of special interest (AESI) method and organ systems-based surveys. The AESI approach focuses on a few events selected based upon their severity, biological plausibility, and previous association with vaccines. Organ systems-based surveys examine systematically any potential side effects that could affect vital organs. The article summarizes the major vaccine safety monitoring systems, including: the U.S Vaccine Adverse Event Reporting System (VAERS), the EU's EudraVigilance System, the Vaccine Safety Datalink (VSD), V-safe, and the Biologics Effectiveness and Safety System (BEST). These systems rely on the AESI approach due to its low cost and simplicity. However, this method is neither sufficiently robust nor sensitive to detect subtle signs of initial endocrine side effects, Dr. Orient writes. 'In fact, one can argue that overreliance on this method can guarantee that virtually none of the endocrine complications of COVID-19 vaccine will be detected.' Induction of autoimmunity is a well-recognized mechanism for vaccine adverse effects. The cause of many endocrine conditions, including diabetes mellitus and thyroid, adrenal, and pituitary diseases, involves autoimmune mechanisms as well. Unsurprisingly, there are published case series and reviews demonstrating association between vaccinations and endocrine disorders, Dr. Orient states. Those phenomena are overlooked by the AESI approach because it lacks needed sensitivity. 'A potential disaster of yet undetected endocrine side effects of the vaccine is likely unfolding surreptitiously,' she concludes, and 'clinicians need to have a high index of suspicion for this problem in their patients.' The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS), a national organization representing physicians in all specialties since 1943. Contact: Jane M. Orient, M.D., (520) 323-3110, janeorientmd@
